-
HBsAg–TBK1 Crosstalk in HBV Immune Evasion
2026-08-20
This Cell Death and Disease study identifies TBK1 as a molecular branch point through which hepatitis B surface antigen suppresses type I interferon signaling while promoting incomplete autophagy. Its combination of interaction mapping, pharmacological perturbation, replication assays, and tissue validation provides a framework for investigating how HBV establishes persistent infection.
-
CBD in Orofacial Inflammatory Pain: Mechanisms
2026-08-20
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce acute and chronic inflammatory pain while also improving pain-associated affective and cognitive abnormalities in mice. Its main innovation is a multi-level mechanism linking peripheral CB2 signaling, central CB1-associated endocannabinoid changes, and serotonin dynamics in the central amygdala.
-
Ruxolitinib, Mitochondrial Fission, and ATC
2026-08-19
The reference study identifies a previously underdefined link between JAK1/2–STAT3 activity, DRP1 transcription, and mitochondrial fission in anaplastic thyroid carcinoma. It shows that Ruxolitinib treatment can promote caspase-dependent apoptosis and GSDME-mediated pyroptosis in cellular and animal models, providing a mechanistic basis for further ATC research rather than clinical proof of efficacy.
-
Norovirus Co-opts NINJ1 for Selective NS1 Secretion
2026-08-19
Song et al. show that murine norovirus repurposes the host membrane protein NINJ1 to release the viral NS1 protein through a caspase-3-dependent unconventional secretion pathway. The work connects regulated membrane rupture, viral immune evasion, and selective cargo recognition, while identifying experimental strategies for dissecting NINJ1-mediated secretion in vivo.
-
2X Taq PCR Master Mix for Plant Virus Workflows
2026-08-18
Pair image-based sweetpotato virus triage with endpoint PCR confirmation using a streamlined, direct-to-gel workflow. This practical guide shows where a dye-containing Taq mix fits in genotyping, cloning, and exploratory plant disease assays—and where it does not replace quantitative or high-fidelity methods.
-
HCAR3 Structures Explain Agonist Recognition
2026-08-18
The 2025 PLOS Biology study uses cryo-EM structures and cellular cAMP assays to define how HCAR3 recognizes selective agonists and differs from HCAR2. Its analysis of binding-pocket geometry and residue-specific interactions provides a mechanistic framework for studying lipid signaling and designing HCAR3-directed ligands.
-
Pentoxifylline, TLR4, and Preterm Monocyte Inflammation
2026-08-17
The reference study shows that pentoxifylline suppresses LPS-driven inflammation in monocytes from preterm and term infants as well as adults, with particularly strong effects on selected preterm-cell markers. By combining flow cytometry, cytokine analysis, phagocytosis assays, and TLR4 transcript measurements, the work links altered monocyte phenotype to reduced TLR4 signaling and provides a useful in vitro framework for neonatal sepsis research.
-
Amiloride (MK-870) in Cell Assays
2026-08-17
This scenario-based guide explains how Amiloride (MK-870), SKU BA2768, can be integrated into cell viability, ion-transport, and endocytosis experiments without confusing pathway modulation with nonspecific cytotoxicity. It combines product-handling data with evidence from a reovirus entry study to support better controls, interpretation, and reagent selection.
-
Ruxolitinib Workflows for JAK1/2 Research
2026-08-16
Ruxolitinib (INCB018424) provides a practical way to interrogate JAK1/JAK2-dependent signaling, hematopoietic progenitor growth, and tumor immune remodeling. This guide connects phospho-signaling assays and colony workflows with high-dimensional immune profiling, including the combination of Ruxolitinib and oncolytic HSV in a murine sarcoma model.
-
HCAR3 Agonist Selectivity: Cryo-EM Insights
2026-08-15
Ye et al. resolve cryo-EM structures of HCAR3 and HCAR2 bound to selective agonists, including Acifran, and identify receptor-pocket features that govern ligand recognition and selectivity. The findings connect structural differences to cAMP signaling and provide a mechanistic framework for developing HCAR3-directed approaches to lipid and metabolic disorder research.
-
Tropisetron Hydrochloride: Assay Workflows
2026-08-14
Build cleaner serotonin receptor signaling research by pairing Tropisetron Hydrochloride with receptor-response assays and transporter-aware controls. This workflow also translates renal OCT2/MATE1 findings into practical cell-based experiments while separating 5-HT3 antagonism from α7-nicotinic receptor activity.
-
Cyclic di-GMP Workflows for Biofilms and STING
2026-08-14
Cyclic di-GMP supports two complementary research paths: mechanistic biofilm formation regulation and STING-centered immune modulation research. This workflow-focused guide covers aqueous handling, assay design, translational applications, and troubleshooting for bacterial persistence and cancer immunotherapy studies.
-
Multiple Myeloma Cell Lines: Mutations and Drug Resistance
2026-08-13
This study provides a comprehensive whole-exome view of 30 human multiple myeloma cell lines, identifying recurrent mutations, altered pathways, and genomic features associated with drug response. Its main practical contribution is a molecular framework for selecting cell models and interpreting resistance experiments in hematological malignancy research.
-
Acifran and the New Logic of HCAR Ligand Selectivity
2026-08-13
Acifran is more than a conventional HCAR agonist: recent cryo-EM evidence positions it as a valuable comparative probe for understanding HCAR2/GPR109A and HCAR3/GPR109B ligand recognition. This thought-leadership guide connects receptor structure, functional assay design, reagent handling, and translational strategy for lipid metabolism and metabolic disorder research.
-
ERK5 and ERK1/2 in Vitamin D–Driven AML Differentiation
2026-08-12
The reference study distinguishes the roles of the ERK5 and ERK1/2 branches of MAPK signaling during 1α,25-(OH)2 vitamin D3-induced differentiation of acute myeloid leukemia cells. Its key contribution is showing that pharmacological ERK5 inhibition can enhance myeloid marker expression while producing cell-cycle arrest, whereas MEK1/2–ERK1/2 inhibition with PD98059 or U0126 suppresses differentiation markers.